CVS Health price target raised to $100 from $89 at BofA

BofA raised the firm’s price target on CVS Health (CVS) to $100 from $89 and keeps a Buy rating on the shares following what the firm calls “a mixed-to-good” Q3 report. The firm thinks the initial EPS guidance of about $7.07 is “a good starting point with significant catalysts over the next year to revise that figure higher,” the analyst tells investors. After the report, BofA increased its 2025 EPS estimate to $6.64 from $6.38 and reduced its 2026 EPS view to $7.09 from $7.34, the analyst noted.